From a pharmacological drugstore viewpoint, Relafen 750, containing naproxen, embodies a fascinating case study in drug action. Its chief mechanism involves blocking cyclooxygenase (COX) enzymes, specifically COX-2, which results in reduced synthesis of pain signals. This specific inhibition reduces swelling and ache associated with conditions like